United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza in patients 1 year and older. - oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral suspens

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules is not recommended f

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. oseltamivir phosphate capsules are contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of the product. severe allergic reactions have included anaphylaxis and serious skin reactions including toxic epidermal necrolysis, stevens-johnson syndrome, and erythema multiforme [see warnings and precautions (5.1)] . pregnancy category c   risk summary there are no adequate and well-controlled studies with oseltamivir phosphate capsules in pregnant women. available published epidemiological data suggest that oseltamivir phosphate capsules, taken in any trimester, is not associated with an increased risk of birth defects. however, these

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules is not recommended f

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 30 mg - oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules are indicated for the prophylaxis of influenza a and b in patients 1 year and older. • oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. • influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology ( 12.4)]. • oseltamivir phosphate capsules are no

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules, usp are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules, usp [ see microbiology (12.4) ] - oseltamivir phosphate c

United States - English - NLM (National Library of Medicine)

alvogen inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 30 mg - oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules are not recom

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 6 mg in 1 ml - oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate for oral suspension is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate for oral suspension is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate for oral

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 30 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules, usp are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules, usp [see micr

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir acid - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp are indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate capsules, usp are indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules, usp are not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules, usp [ see microbiology (12.4) ] - oseltamivir phosphate c